Preventing and reversing neuroinflammatory brain damage using local expansion of...
Preventing and reversing neuroinflammatory brain damage using local expansion of regulatory T cells
"A proposal to use local IL2 delivery via a viral vector to prevent and reverse the inflammatory damage that happens to the brain during neuroinflammatory diseases as diverse as traumatic brain injury, Multiple Sclerosis and Alzhe...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto TreatBrainDamage
Duración del proyecto: 21 meses
Fecha Inicio: 2020-05-09
Fecha Fin: 2022-02-28
Líder del proyecto
THE BABRAHAM INSTITUTE
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"A proposal to use local IL2 delivery via a viral vector to prevent and reverse the inflammatory damage that happens to the brain during neuroinflammatory diseases as diverse as traumatic brain injury, Multiple Sclerosis and Alzheimer's Disease. In ""TissueTregs"" we identified and characterised a brain-resident regulatory T cell population, with high expression of anti-inflammatory and reparative proteins. A synthetic circuit for deliver IL2 to the brain expanded this population, without any off-target increases in circulation or the blood. In order to translate these findings beyond the scope of the original ""TissueTregs"" grant, we have moved to a viral vector system, designed to give brain-specific expression of IL2. This systems demonstrates long-lasting brain-specific expansion of the brain-resident regulatory T cell population, after only a single intravenous injection. Preliminary results demonstrate a striking ability of this treatment to prevent neurological damage in mouse models of traumatic brain injury and Multiple Sclerosis. A provisional patent has been filed to cover this invention. In this PoC grant, we will run the necessary validation and target deconvolution experiments to pave the way for this treatment to move into the clinical sphere."